Bloomberg Intelligence: Pfizer's Obesity Pill Setback, Boeing's China Orders, LVMH Earnings & More

Pfizer's Obesity Pill Development Halted

• 💊 Pfizer has terminated development of its obesity pill, Danuglipron, due to patient liver injury concerns.
• 💡 This setback raises the possibility of Pfizer needing to acquire external assets to compete in the lucrative obesity market, estimated at over $100 billion.
• 📉 Pfizer faces significant revenue loss from patent expirations and needs new growth drivers, with obesity pills being a key potential pillar.
• 🚀 Competitors like Eli Lilly and Novo Nordisk have existing or upcoming obesity treatments, highlighting the urgency for Pfizer.

Boeing Faces China Delivery Halt Amid Trade Tensions

• ✈️ China has ordered its airlines to stop taking deliveries of Boeing jets and halt purchases of related US equipment as a retaliatory trade measure.
• ⚠️ Analysts view this as largely symbolic, as Chinese airlines had already significantly reduced Boeing orders in recent years.
• 📈 Boeing's primary challenge is delivering existing aircraft and managing its